VJHemOnc Podcast
iwMyeloma Session I: genomics of high-risk and smoldering multiple myeloma
Apr 12, 2023
Leif Bergsagel, MD, Mayo Clinic, Phoenix, AZ, and Francesco Maura, MD, Sylvester Comprehensive Cancer Center, discuss genomics of high-risk and smoldering multiple myeloma. Topics cover next-generation sequencing (NGS), del(17p) and TP53 mutations, high-risk factors, controversy surrounding 17P deletion and TP53 mutation, challenges in determining and targeting cancer cells.
13:37
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Immunoglobulin transcription consistently decreases as myeloma progresses, highlighting the importance of accurate risk assessment.
- Next-generation sequencing is a significant development in myeloma research, allowing for better understanding of risk factors and improved patient outcomes.
Deep dives
Genomics of High Risk Myeloma and Smoldering Myeloma
The podcast episode discussed the genomics of high risk myeloma and smoldering myeloma. One key point addressed was the level of immunoglobulin transcription, which consistently decreases as the disease progresses from normal plasma cell to smoldering myeloma to multiple myeloma. Next-generation sequencing was highlighted as an important tool in analyzing the genetic features of these conditions. The experts also discussed the crucial role of deletion 17p and TP53 mutations in determining prognosis, emphasizing the need for accurate risk assessment in myeloma.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
